anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hip fractures are becoming a more prevalent issue worldwide, leading to profound morbidity, and in some cases, mortality. Currently the most common method of surgical treatment includes the use of a sliding hip screw over a Gamma intramedullary nail, but there is conflicting evidence regarding which device has a lower revision of surgery rate and complication rate. The newest generation of Gamma3 nails have strong rationale suggesting significantly decreased rates of femoral shaft fractures and improved function. The improvements in implant design of the Gamma3 nail provide compelling rationale for the conduct of a large, definitive trial, and therefore a pilot study is being conducted to confirm or refute our ability to recruit patients and assess the consistency between site estimates and actual recruitment, determine the degree to which site investigators can adhere to trial protocol, confirm or refute our anticipated ability to achieve close to 100% follow- up, assess our ability to maintain 100% data quality, field test our case report forms for clarity and appropriateness, and to determine whether we can successfully manage the logistics of coordinating trial activities across multiple sites.

This trial is a pilot, multi-center, concealed randomized controlled trial. Surgeons will use one of the two surgical strategies in patients who have sustained a trochanteric fracture; the Gamma3 intramedullary nail or the sliding hip screw. Clinical assessments will occur at the time of hospital admission, 1 week, 3 months, 6 months, and 12 months after surgery.
Invention describes pharmaceutical delivery systems comprising 7-dimethyl-6-deoxy-6-demethyltetracycline and it salt which is formed during addition reaction with non-toxic acid. The smaller part of a mixture of substances in these delivery systems contains slowly releasable spherical granules coated by polymer mixture. These granules release part of minocycline in a medium with pH less than 3,9 and the remaining part in the medium with pH from about 4,0 to about 7,5. The largest part of the mixture of substances contains coated and uncoated fast releasing granules which can release minocycline in a medium with pH less than 3,9 as well as capsules containing one oral dose of minocycline. These delivery systems ensure high therapeutical level of minocycline in blood at least 24 hours when it is administered once a day. It is not important whether a patient abstains from food or is fed. Invention also describes methods for producing these delivery systems and compositions.
OBJECTIVE: Prevention of late type Ia endoleaks is the main concern in thoracic endovascular aortic aneurysm repair (TEVAR) for thoracic aortic aneurysm. Since 2017, we have performed zone 0 TEVAR with proximal fixation augmentation using a Najuta thoracic fenestrated stent graft in addition to zone 2 TEVAR for distal arch aneurysms. We report the early and midterm outcomes of TEVAR performed using this strategy.
METHODS: This single-center retrospective study enrolled 386 cases of TEVAR for thoracic aortic disease between January 2013 and December 2020. Patients with thoracic aortic aneurysm treated by TEVAR landing at zone 2 was referred to as the standard group, whereas those treated by TEVAR landing at zone 0 using a Najuta fenestrated stent graft in addition to zone 2 TEVAR was referred to as the augmentation group. We retrospectively compared the clinical outcomes between the two groups. The primary end point was secondary intervention for postoperative type Ia endoleaks. Secondary end points were technical success, aneurysm-related death, and major adverse events (MAEs), including stroke, paraplegia, endoleaks, and secondary interventions.
RESULTS: We performed TEVAR in 41 and 30 cases in the standard and augmentation groups, respectively. The mean aneurysm sizes in the standard and augmentation groups were 54.5 and 57.3 mm (P = .23), and the proximal neck lengths were 16.8 and 17.4 mm (P = .65), respectively. The anatomical characteristics seemed to be similar in both groups. The technical success rate in both groups was 100%. Three cases in the standard group had MAEs, including two stroke and one brachial artery pseudoaneurysm; whereas two cases had MAEs in the augmentation group, including one stroke and one paraplegia. There was no 30-day mortality or retrograde type A dissection in both groups. The mean observation periods in the standard and augmentation groups were 46 months (range, 1-123 months) and 35 months (range, 1-73 months), respectively. At 36 and 60 months after the procedure, the freedom from aneurysm-related death was 97.6% and 97.6% in the standard group, 100.0% and 100.0% in the augmentation group (P = .39); and the freedom from reintervention for type Ia endoleaks was 79.2% and 65.2% in the standard group, 100.0% and 100.0% in the augmentation group (P = .0087). A statistically significant decrease in reinterventions for type Ia endoleaks was observed in the augmentation group.
CONCLUSIONS: Proximal fixation augmentation using the Najuta fenestrated stent graft during TEVAR for distal arch aneurysm is effective in preventing the postoperative late type Ia endoleaks.
Patients with PD complete motor response inhibitions tasks under multiple conditions, depending on the study aim they are participating in. Those who are participants in Aim 1 of the study are able to also participate in Aims 2 and 3 if they are having a clinically indicated DBS leads implanted. Patients with PD will participate in the study for approximately 18 months which includes one preoperative visit, intraoperative data collection and two post-operative visits. As part of the motor inhibition tasks, EEG signals will be recorded. A cap similar to a swim cap will be placed on the head of the subject, and gel will be applied to the hair to get a good signal. Electrodes will be attached to the cap for recording of brain signals. A few additional flat electrodes will be placed on the skin to record hand muscle activity (for GNG task) and near the eyes to record eye movements. Accelerometer sensors will be utilized to record arm movements (for MSS task).
Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
Studied products will be applied as per the patient information leaflet following manufacturer guidelines to the treatment area. The studied products will be used starting on the first day of radiation therapy. The studied products will be applied twice a day to the entire treatment field. The studied products will be used during the entire course of radiotherapy and for a further 4 weeks upon completion of radiation therapy.
Quinones are reduced to hydroquinones and/or hydroquinones are stabilized by treating a quinone or hydroquinone with an aqueous alkaline solution of an alkali metal borohydride.  Such solution may be used for dyeing keratinous material such as wool or hair, and the hydroquinone oxidized on the fibre, the pH being reduced to destroy the borohydride if desired, or the oxidation may take place in alkaline solution.  A primary aliphatic or arylaliphatic amine and an antifoaming agent may be present in the dye solution. The rate of reduction to hydroquinone may be speeded up in some cases by the addition of alcohols.  Quinones specified are benzoquinone, hydroxybenzoquinone, methoxybenzoquinone, 2-aminobenzoquinone, 2,5-bis - diethylamino-benzoquinone, anilinoquinone, 2,5-dihydroxybenzoquinone, 2,5-dimethoxybenzoquinone, chloroquinone, 1,4-naphthoquinone, lawsone, juglone, menaphthone, 2-amino - 1,4 - naphthoquinone, 1,2 - naphthoquinone-4-sulphonic acid sodium salt, 2,3-dichlor - 1,4 - naphthoquinone, naphthazarin, indigo, alizarin. In examples: (1) lawsone, juglone and naphthazarin are each ground with potassium borohydride and the mixtures added to water, the solutions are subsequently acidified or reduced in pH by addition of a buffer, and used to dye hair and wool cloth.  Also in examples: (2) mixtures of (a) trihydroxybenzene and lawsone, (b) lawsone and juglone, (c) juglone and naphthazarin, and (d) lawsone, juglone and naphthozarin are similarly treated.ALSO:Quinones are reduced to hydroquinones and/or hydroquinones are stabilized by treating a quinone or hydroquinone with an aqueous alkaline solution of an alkali metal borohydride.  Such solutions may be used for dyeing keratinous material such as wool or hair, and the hydroquinone oxidized on the fibre, the pH being reduced to destroy the borohydride if desired, or the oxidation may take place in alkaline solution.  A primary aliphatic or arylaliphatic amine and an antifoaming agent may be present in the dye solution. The rate of reduction to hydroquinone may be speeded up in some cases by the addition of alcohols.  Quinones specified are benzoquinone, hydroxy benzoquinone, methoxybenzoquinone, 2 - aminobenzo, quinone, 2.5 - bis - diethylamino - benzoquinone, anilinoquinone, 2.5 - dihydroxy-benzoquinone, 2.5 - dimethoxybenzoquinone, chloroquinone, 1.4 - naphthquinone, lawsone, juglone, menaphthone, 2-amino - 1.4 - naphtho quinone, 1.2 - naphthoquinone - 4 - sulphonic acid sodium salt, 2.3-dichlor- 1.4naphthoaquinone naphthazarin, indigo, alizarin. In examples, (1) lawsone, juglone and naphthazarin are each ground with potassium borohydride and the mixture added to water, the solutions are subsequently acidified or reduced in pH by addition of a buffer, and used to dye hair and wool cloth.  Also in examples (2) mixtures of (a) trihydroxybenzene and lawsone, (b) lawsone and juglone, (c) juglone and naphthazarin, and (d) lawsone, juglone and naphthazarin are similarly treated.
Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
OBJECTIVES: To discriminate between post-treatment changes and tumor recurrence in patients affected by glioma undergoing surgery and chemoradiation with a new enhancing lesion is challenging. We aimed to evaluate the role of ASL, DSC, DCE perfusion MRI, and 18F-DOPA PET/CT in distinguishing tumor recurrence from post-treatment changes in patients with glioma.
MATERIALS AND METHODS: We prospectively enrolled patients with treated glioma (surgery plus chemoradiation) and a new enhancing lesion doubtful for recurrence or post-treatment changes. Each patient underwent a 1.5T MRI examination, including ASL, DSC, and DCE PWI, and an 18F-DOPA PET/CT examination. For each lesion, we measured ASL-derived CBF and normalized CBF, DSC-derived rCBV, DCE-derived Ktrans, Vp, Ve, Kep, and PET/CT-derived SUV maximum. Clinical and radiological follow-up determined the diagnosis of tumor recurrence or post-treatment changes.
RESULTS: We evaluated 29 lesions (5 low-grade gliomas and 24 high-grade gliomas); 14 were malignancies, and 15 were post-treatment changes. CBF ASL, nCBF ASL, rCBV DSC, and PET SUVmax were associated with tumor recurrence from post-treatment changes in patients with glioma through an univariable logistic regression. Whereas the multivariable logistic regression results showed only nCBF ASL (p = 0.008) was associated with tumor recurrence from post-treatment changes in patients with glioma with OR = 22.85, CI95%: (2.28-228.77).
CONCLUSION: In our study, ASL was the best technique, among the other two MRI PWI and the 18F-DOPA PET/CT PET, in distinguishing disease recurrence from post-treatment changes in treated glioma.
PURPOSE:To judge the resin powder having the required grain size in use by coloring the flammable resin powder having the grain size within a specific range with a water soluble dye. CONSTITUTION:Flammable resin powder having the grain size of 30-800mum and a spherical or unspecified shape is colored with a water soluble dye. When the grain size is 30mum or below, the resin powder is buried in an adhesive, or the undercut becomes too small because the grain size is very fine. When the grain size is 800mum or above, the opaque layer becomes too thick, and it can not be used in view of color tone reproducibility. The water soluble dye of 0.001-10 pts.wt. and the resin powder of 0.1-100 pts.wt. are combined with water of 100 pts.wt. for coloring. When the water soluble dye is below 0.001 pts.wt., the color tone of the colored resin powder becomes too light, the color tone of a wax pattern transmits the resin powder, the discrimination property between the wax pattern and the resin powder is deteriorated. When the water soluble dye exceeds 10 pts.wt., the color tone of the colored resin powder becomes too deep, and the discrimination property with a wax pattern having dark color tone is deteriorated. When the resin powder exceeds 100 pts.wt., it can not be stirred at the time of coloring, and no uniform color tone is obtained.
BACKGROUND: The prevalence of chronic non-specific neck pain (CNNP) is on the rise among the young adult population. We herein aimed to compare the effects of long-term specific cervical extensor training and stretching exercises on improving this chronic disorder in young adults.
METHODS: In this prospective, randomized, controlled study, 70 participants aged 18-35 years with CNNP and cervical lordosis loss were included. The participants were assigned to undergo either specific cervical extensor training (observation group) or perform usual stretching exercises (control group). The exercise duration was set at 12 months, with 9 months at the clinic and 3 months at home. The outcome assessments included changes in the neck disability index, visual analog scale from baseline, cervical range of motion (CROM), cross-sectional areas (CSAs) of cervical extensors, and cervical curvature from baseline. The outcome measures were compared between groups at 3, 6, and 12 months of follow-up.
RESULTS: All 70 participants underwent randomization, and no significant differences in demographics and baseline data were found between the two groups. The observation group showed a greater improvement in neck disability index and visual analog scale scores at the 12-month follow-up than the control group. Additionally, a more substantial increase in CROM and CSAs of cervical extensors was observed in the observation group at the 6-month and 12-month follow-ups (P < 0.05). Although more participants in the observation group achieved cervical lordosis at the 12-month follow-up, the difference was marginally nonsignificant (9% in the control group vs. 28% in the observation group, P = 0.075).
CONCLUSIONS: In young adults with CNNP, long-term specific cervical extensor training was associated with a more significant clinically meaningful improvement in disability, pain, and CROM than stretching exercises. The increased CSAs of cervical extensors may potentially contribute to the restoration of cervical lordosis. Trial registration The study is registered at the Chinese domestic clinical trial (ChiCTR2000040009) at Chictr.org. The date of registration: November 18, 2020.
OBJECTIVES: Although the dorsal pancreatic artery (DPA) is an important artery that supplies the pancreas, its morphology has not been sufficiently studied. We investigated the morphology of the DPA and the progression of pancreatic cancer along this vessel.
MATERIALS AND METHODS: Overall, 142 patients with pancreatic cancer who underwent surgical resection at Kanazawa University Hospital between 2004 and 2015 were enrolled. We examined the morphology of the DPA using preoperative computed tomography and cancer progression along the DPA using resected specimens. We investigated the anatomical structures surrounding the DPA through cadaveric examination.
RESULTS: The analysis of computed tomography images revealed the presence of the DPA in 141 patients. In typical cases, the DPA divides into a head and a body branch. Histopathological examination revealed cancer progression along the DPA in 32 patients. Cancer progression along the DPA was identified as a factor associated with a poor prognosis in pancreatic head or body cancer. Cadaveric examination showed the presence of abundant nerve and lymphatic tissues along the DPA.
CONCLUSIONS: It is important to remove the soft tissue surrounding the DPA during surgery for pancreatic head or body cancer because it may serve as an important route for cancer progression.
QT prolongation, Torsades de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with clozapine treatment. When prescribing clozapine, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.

Prior to initiating treatment with clozapine, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue clozapine if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes or other arrhythmias (e.g., syncope, presyncope, dizziness, or palpitations), obtain a cardiac evaluation and discontinue clozapine.

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine orally disintegrating tablets. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Clozapine is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of clozapine orally disintegrating tablets [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. 

Hypokalemia and hypomagnesemia increase the risk of QT prolongation. Hypokalemia can result from diuretic therapy, diarrhea, and other causes. Use caution when treating patients at risk for significant electrolyte disturbance, particularly hypokalemia. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with clozapine.
BACKGROUND: A multidisciplinary approach is required for the management of long COVID. The aim of this study was to determine the feasibility (demand, implementation, practicality, acceptability, and limited efficacy) of an allied-health-led multidisciplinary symptom management service (ReCOV) for long COVID.
METHODS: A single-group observational cohort feasibility study was conducted to determine demand (referrals), acceptability (survey), implementation (waitlist times, health professions seen), practicality (adverse events), and limited efficacy (admission and discharge scores from the World Health Organization Disability Assessment Scale, Brief Illness Perception Questionnaire (BIPQ), Patient Health Questionnaire, and EuroQol 5D-5L). Data are presented as median [interquartile range] or count (percentage).
RESULTS: During the study, 143 participants (aged 42.00 [32.00-51.00] years, 68% women) participated in ReCOV. Participants were waitlisted for 3.86 [2.14-9.86] weeks and engaged with 5.00 [3.00-6.00] different health professionals. No adverse events occurred. The thematic analysis revealed that ReCOV was helpful but did not fully meet the needs of all participants. Limited efficacy testing indicated that participants had improved understanding and control (p < 0.001) of symptoms (BIPQ) and a small improvement in EQ VAS score (median difference 5.50 points [0.00-25.00], p = 0.004]).
CONCLUSIONS: A multidisciplinary service was safe and mostly acceptable to participants for the management of long COVID. Further research should investigate the clinical and cost effectiveness of such a service, including optimal service duration and patient outcomes.
OBJECTIVE: Aim: To estimate the frequency of different types of healthcare-associated maternal peripartum infections and their risk factors among women in Ukraine.
PATIENTS AND METHODS: Materials and Methods: Multicenter prospective cohort study was conducted in nine regional perinatal centers of Ukraine between January 1, 2021, to December 31, 2023. The criteria for specific healthcare-associated maternal peripartum infections (endometritis, episiotomy infection, and maternal sepsis) site were adapted from the CDC/NHSN case definitions. Surveillance was performed during the hospitalization period and up to 30 days after hospital discharge.
RESULTS: Results: A total of 3600 deliveries by the vaginal route were performed during the study period, 600 (16.7%) maternal peripartum infections were observed. Of all maternal peripartum infection cases, 79.7% were detected after hospital discharge. The most common maternal peripartum infections include endometritis (54.8%), episiotomy infections (34.4%), and maternal sepsis (10.8%). According to the multivariate logistic regression analysis, the body mass index >25, placenta previa, premature rupture of membrane, prolonged rupture of membranes, manual removal of the placenta, multiple vaginal examinations, bacterial vaginosis, aerobic vaginitis, gestational diabetes mellitus, and anemia during pregnancy were independent risk factors for maternal peripartum infections.
CONCLUSION: Conclusions: Results this study suggest a high prevalence of healthcare-associated maternal peripartum infections in Ukraine. Several factors have been associated with increased risk of maternal peripartum infections, including pre-existing maternal conditions, placenta previa, prolonged rupture of membranes, and spontaneous or provider-initiated conditions during labour and childbirth.
The utility model relates to combined percutaneous cream for treating male impotence and premature ejaculation. At present, male sexual disfunction influences the quality of the life of people increasingly. Therefore, the utility model provides a combined percutaneous cream for treating male impotence and premature ejaculation. The combined percutaneous cream is in tubular structure, and an interlayer (3) is arranged in the middle part. The tubular structure is divide into an impotence treatment section (1) and a premature ejaculation treatment section (2) which are mutually connected and are independent, and the openings of the impotence treatment section (1) and the premature ejaculation treatment section (2) are sealed by covers (4), wherein, pharmaceutical (5) for treating impotence of effective dose is arranged in the impotence treatment section (1), and pharmaceutical (6) for treating premature ejaculation of effective dose is arranged in the premature ejaculation treatment section (2). The utility model has the advantages of convenient treatment, security, comfort, little side effect, good confidentiality and conspicuous effect.